Literature DB >> 16113464

Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease.

Robert Naeije1.   

Abstract

Pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD). The increase in pulmonary artery pressures is often mild to moderate. However, 5-10% of patients with advanced COPD may suffer from severe pulmonary hypertension and present with a progressively downhill clinical course because of right heart failure added to ventilatory handicap. The prevalence of clinically significant severe pulmonary hypertension in COPD is roughly estimated to be of 1-2/1,000. The cause of pulmonary hypertension in COPD is generally assumed to be hypoxic pulmonary vasoconstriction leading to permanent medial hypertrophy. However, recent pathologic studies point rather at extensive remodeling of all layers of the pulmonary arterial walls. These aspects account for minimal reversibility with supplemental oxygen. There may be a case for pharmacologic treatment of pulmonary hypertension in selected patients with advanced COPD and right heart failure. However, it will be a challenge for randomized controlled trials to overcome the difficulties of the diagnosis of right ventricular failure and the definition of a relevant primary endpoint in pulmonary hypertensive patients with COPD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113464     DOI: 10.1513/pats.200407-037MS

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  40 in total

Review 1.  [Comorbidities of COPD].

Authors:  H Watz; H Magnussen
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

2.  Clinical, historical and diagnostic findings associated with right ventricular dysfunction in patients with central and non-massive pulmonary embolism.

Authors:  Domenico Rendina; Silvana De Bonis; Giovanni Gallotta; Vincenzo Piedimonte; Giuseppe Mossetti; Gianpaolo De Filippo; Francesca Farina; Giuseppe Vargas; Maria Rosaria Barbella; Alfredo Postiglione; Pasquale Strazzullo
Journal:  Intern Emerg Med       Date:  2009-11-25       Impact factor: 3.397

Review 3.  Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence.

Authors:  Gülmisal Güder; Frans H Rutten
Journal:  Curr Heart Fail Rep       Date:  2014-09

Review 4.  Drug abuse and HIV-related pulmonary hypertension: double hit injury.

Authors:  Zachery J Harter; Stuti Agarwal; Pranjali Dalvi; Norbert F Voelkel; Navneet K Dhillon
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

5.  EXPRESS: Gremlin1 blocks vascular endothelial growth factor signalling in the pulmonary microvascular endothelium.

Authors:  Simon Coyle Rowan; Lucie Piouceau; Joanna Cornwell; Lili Li; Paul McLoughlin
Journal:  Pulm Circ       Date:  2018-10-04       Impact factor: 3.017

Review 6.  Balancing the risks and benefits of oxygen therapy in critically III adults.

Authors:  G R Scott Budinger; Gökhan M Mutlu
Journal:  Chest       Date:  2013-04       Impact factor: 9.410

Review 7.  Differential assessment and management of asthma vs chronic obstructive pulmonary disease.

Authors:  Barbara P Yawn
Journal:  Medscape J Med       Date:  2009-01-21

8.  Hypoxia-induced endothelial CX3CL1 triggers lung smooth muscle cell phenotypic switching and proliferative expansion.

Authors:  Jianliang Zhang; Hanbo Hu; Nadia L Palma; Jeffrey K Harrison; Kamal K Mubarak; Robin D Carrie; Hassan Alnuaimat; Xiaoqiang Shen; Defang Luo; Jawaharlal M Patel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-09-21       Impact factor: 5.464

Review 9.  Targeted treatment in COPD: a multi-system approach for a multi-system disease.

Authors:  David Anderson; William Macnee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-01

Review 10.  Update on pulmonary hypertension complicating chronic obstructive pulmonary disease.

Authors:  Soma Jyothula; Zeenat Safdar
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.